Tagged with R

MEA Rare diseases remain among the most complex and least visible challenges facing healthcare systems, particularly in regions where genetic factors amplify the burden. In this conversation, Ahmed Salem, Head of AstraZeneca Rare Diseases in the Gulf, reflects on how rare disease strategy is translated into regional action, spanning innovation, diagnostics,…

France France finally has a full budget for 2026, ending months of stasis, and providing a degree of certainty to industry. However, especially for pharma, continual price cuts threaten the sustainability of France as an investment destination, although the reindustrialisation incentives contained with the ‘France 2030’ plan are leading to an…

Global Jerry Radich of the Fred Hutchinson Cancer Center, writing in the February 2026 edition of DIA’s Global Forum magazine, lays out a framework for taking cutting-edge cancer therapies – currently the preserve of the world’s wealthiest nations – to a broader global patient population.   It’s been said that geography…

USA Patients and carers with lived experience of a disease have valuable insights to share with physicians and drug developers alike. This is especially true of rare diseases, defined in the US as those that affect fewer than 200,000 people nationwide and which collectively impact over 30 million Americans. For these…

Taiwan Dr Tom Tang, CEO of Maxima, discusses the company’s strategic positioning in the surgical energy device market, Taiwan’s emerging role in global medical technology manufacturing, and his vision for creating a replicable business model that could catalyse the nation’s medtech industry. With a USD 19.5 billion market opportunity and plans…

Taiwan Dr Jung-Chi Liao, CEO and Founder of Syncell, explains how his company is creating a new category in protein identification through its microscopy-guided protein extraction technology. Trained as a mechanical engineer with a PhD from MIT and later conducted biological research for 25 years since his postdoctoral work at Berkeley,…

MEA As healthcare systems across the GCC accelerate their focus on innovation, access, and advanced therapies, Novartis is positioning the region at the centre of its long-term strategy. Mohamed Ezz Eldin shares how global priorities are translated into local execution, from rare disease care and genomics to clinical research and innovative…

USA Tony Zook reflects on how decades in pharmaceutical leadership inform his perspective on diagnostics as the backbone of precision oncology. This discussion traces NeoGenomics’ evolution from a haematology specialist to a broader oncology platform spanning therapy selection, next-generation sequencing (NGS), and molecular residual disease (MRD). Set against the realities of…

MEA Biogen’s transformation into a rare disease-focused organisation is reshaping how innovation reaches patients in the GCC. Diederik Kok, the company’s GCC Head reflects on how global strategy translates into regional execution, from launching first-in-class therapies and navigating access for ultra-rare conditions, to building sustainable financing models, clinical research capacity, and…

MEA Hussein Abhari, Head of the MENA region, QIAGEN, has led the company’s regional presence since 2017, spanning products for molecular research and clinical testing. His priorities focus on strengthening long-term partnerships, supporting national healthcare strategies, building local scientific capacity and ensuring advanced molecular and genetic technologies translate into real-world clinical…

USA Dr Anthony Letai reflects on how a career spanning cancer biology, clinical oncology, and translational research is shaping his early priorities as Director of the National Cancer Institute. The conversation examines how NCI is navigating a shifting global research landscape while accelerating innovation, strengthening evidence-based decision-making, and reinforcing confidence across…

Taiwan Since arriving at Organon Taiwan two years ago, Robert Mitchell has focused on growing patient access, revenue, and investments while strengthening the team. Robert explains how he is prioritising government partnerships, sustainable supply chains, and women’s health innovation, while fostering an inclusive culture, digitalisation, and talent development.   We are…